Seeking Alpha

Allergan (AGN +0.5%) and Molecular Partners have entered into two separate agreements to...

Allergan (AGN +0.5%) and Molecular Partners have entered into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases, with a specific emphasis on age-related macular degeneration.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector